Meet with Accelovance at ESMO 2017

    ESMO Congress Madrid 2017

    Are You Attending ESMO Congress Madrid 2017?

    Reserve Your Meeting With Accelovance

    Whether you're still in the early planning phase or you have a compound ready for clinical testing, we are a leading oncology CRO helping you advance your promising cancer therapy. 

    In addition to our conventional oncology CRO services, Accelovance's specialized HERO Initiative (Helping Early Research in Oncology) is a program dedicated to supporting your Phase I/II program needs. HERO is specifically designed to expedite your trial timeline and lower project costs, to advance your compound to the next stage. The benefits of HERO include:

    • Dedicated oncology site network of 250+ cancer research centers
    • Faster start-up times averaging 6-12 weeks
    • Rapid recruitment with a robust patient pipeline and just-in-time enrollment solutions
    • Turnkey technology solutions tailored for early phase cancer research

    Set up a meeting and discover how HERO aligns with your project needs. Ask us about the advantages of running your immuno-oncology program in the US.

    We know your schedule will book up fast, so go ahead and reserve your meeting time. Or stop by Booth #27 in the Technology Exhibition Hall.

     

    Reserve Your Meeting Time

     

     Meet The Accelovance Oncology Team

    While at ESMO, our Oncology experts will be available to meet with you and advise on upcoming projects. Accelovance's scientific experts bring a wealth of knowledge to cancer research.

    Jamie_Oliver.jpg Harish_Dave_CMO.jpg

    Jamie Oliver,  Pharm. D.

    Chief Scientific Officer

    Dr. Jamie Oliver, Chief Scientific Officer, has supported more than 25 FDA submissions (IND to NDA) for oncology drugs and biologics. His extensive experience covers biologics, small molecule and nanoparticle oncology products. His breadth of work allows him to effectively guide Sponsors to optimize your programs from pre-clinical to NDA.  Dr. Oliver provides input and development strategies as part of Accelovance's oncology consulting team in collaboration with Harish Dave, Chief Medical Officer.

    Harish Dave, M.D.

    Chief Medical Officer

    Dr. Harish Dave, board certified oncologist, has been involved in over 100 clinical trials.  As our Chief Medical Officer, he leads our Medical Affairs & Drug Safety group where he leverages over 25 years' experience gained from academia, as a principal investigator, and industry professional.  Dr. Dave provides input and development within our Oncology consulting team along with Jamie Oliver, Chief Scientific Officer.

     

    Jamie and Harish's schedules will fill up fast, so be sure to reserve your meeting today!

     

    Reserve Your Meeting Time

     

    Can't Make It To ESMO This Year?

    Can't make it to Madrid for ESMO this time? No worries, we realize it's a busy time of year. Reach out to us for more information about our services for your next oncology clinical trial.

     

    Get More Information

     

    About Accelovance

    Accelovance is an award-winning, clinical development CRO focused on oncology and immunological vaccine programs across phase I-IV. The HERO Initiative by Accelovance is a specialized early phase oncology program providing emerging and established biotech and pharmaceutical companies an accelerated means of advancing their early phase cancer compounds through clinical testing. Learn more about our services: 

    Meet Us At ESMO